GRFS

Grifols SA ADR

GRFS, USA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.

https://www.grifols.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GRFS
stock
GRFS

Portfolio Recap: How GRFS stock compares to growth peers - Layoff News & Daily Oversold Stock Bounce Ideas moha.gov.vn

Read more →
GRFS
stock
GRFS

State of Wyoming Invests $1.73 Million in Grifols, S.A. $GRFS MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$12.525

Analyst Picks

Strong Buy

1

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

13.81

Low 50

High 10

Price to Book Ratio (P/B)

-

Very Low

1.20

Low 1

High 3

Return on Equity (ROE)

-

Very Low

2.45 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

0.64 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

13.69 %

Low 5%

High 15%

Debt to Equity

-

Very Low

2.38

Low 1

High 0.3

Investors

* Institutions hold a combined 28.73% of the total shares of Grifols SA ADR

1.

Brandes Investment Partners & Co

(4.1198%)

since

2025/06/30

2.

Capital World Investors

(3.1818%)

since

2025/06/30

3.

Permian Investment Partners

(2.7373%)

since

2025/06/30

4.

Capital Group New Perspective Comp

(2.063%)

since

2025/06/30

5.

American Funds New Perspective A

(2.063%)

since

2025/06/30

6.

Black Creek Investment Management Inc

(1.8471%)

since

2025/06/30

7.

Millennium Management LLC

(1.4206%)

since

2025/06/30

8.

Armistice Capital, LLC

(1.0724%)

since

2025/06/30

9.

Soleus Capital Management, L.P.

(0.846%)

since

2025/06/30

10.

American Funds Intl Gr and Inc F2

(0.6161%)

since

2025/06/30

11.

Capital Group Intl Growth & Inc Comp

(0.6161%)

since

2025/06/30

12.

Brandes International Small Cap Equity A

(0.5608%)

since

2025/06/30

13.

United International Eq Alpha Corp Cl A

(0.511%)

since

2025/03/31

14.

HHG PLC

(0.4702%)

since

2025/06/30

15.

Harris Associates L.P.

(0.4593%)

since

2025/06/30

16.

Bank of America Corp

(0.4434%)

since

2025/06/30

17.

CI International Equity Fund F

(0.4211%)

since

2024/12/31

18.

Whitebox Advisors, LLC

(0.3852%)

since

2025/06/30

19.

New York State Common Retirement Fund

(0.3604%)

since

2025/06/30

20.

Oakmark International Small Cap Investor

(0.326%)

since

2025/06/30

21.

Brandes International Small Cap Eq

(0.3258%)

since

2025/06/30

22.

UBS Group AG

(0.3246%)

since

2025/06/30

23.

SEI Investments Co

(0.3059%)

since

2025/06/30

24.

Brandes Global Small Cap Equity Cl F

(0.2978%)

since

2025/08/31

25.

Pictet Asset Manangement SA

(0.2922%)

since

2025/06/30

26.

NORGES BANK

(0.2851%)

since

2025/06/30

27.

Morgan Stanley - Brokerage Accounts

(0.2813%)

since

2025/06/30

28.

JPMorgan Chase & Co

(0.2775%)

since

2025/06/30

29.

Black Creek International Equity CIT A

(0.2481%)

since

2025/06/30

30.

Flat Footed LLC

(0.2402%)

since

2025/06/30

31.

BlackRock Inc

(0.2189%)

since

2025/06/30

32.

CI Global Balanced Fund F

(0.1833%)

since

2024/12/31

33.

Pictet-Global Megatrend Sel I USD

(0.1558%)

since

2025/05/31

34.

Capital Group GlbNewPers (LUX) P

(0.1505%)

since

2025/05/31

35.

iShares Biotechnology ETF

(0.1451%)

since

2025/08/31

36.

MGI Global Equity M-7 € Acc

(0.1156%)

since

2025/07/31

37.

Pictet-Health I USD

(0.0983%)

since

2025/05/31

38.

CI Global Balanced Corporate F

(0.0966%)

since

2025/08/31

39.

Brandes Global Equity F

(0.0874%)

since

2025/08/31

40.

Brandes International ETF

(0.0794%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

0.2183

EPS Estimate

0.2314

EPS Difference

-0.0131

Surprise Percent

-5.6612%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Moderately Defensive(3.5)
Dividend
Decent Dividend Payer(3.5)
Economic Moat
Wide Moat Company(6.8)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(3.5)
Momentum
Moderate Momentum(4.5)
Net Net
Possible Net-Net(4)
Quality
Moderate Quality(4.5)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.